Showing results (481-490 of 671) with videos related to

Sort By:
Pageof 68
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Characterization and Comparison of GITR Expression in Solid TumorsLuis Vence, Samantha L Bucktrout, Irina Fernandez Curbelo, et al.
Nature Reviews. Cancer|October 1, 2024
Defining precancer: a grand challenge for the cancer communityJessica Faupel-Badger, Indu Kohaar, Manisha Bahl, et al.
Scientific Reports|July 27, 2017
Thy-1<sup>+</sup> Cancer-associated Fibroblasts Adversely Impact Lung Cancer PrognosisMark J Schliekelman, Chad J Creighton, Brandi N Baird, et al.
Nature|February 4, 2021
Elevated NSD3 histone methylation activity drives squamous cell lung cancerGang Yuan, Natasha M Flores, Simone Hausmann, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancerVladimir Roudko, Diane Marie Del Valle, Emir Radkevich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 3, 2023
Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained ImagesZhuoyu Wen, Danni Luo, Shidan Wang, et al.
Nature Communications|November 4, 2018
Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancerMauricio S Caetano, Maya Hassane, Hieu T Van, et al.
Cancers|May 30, 2019
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective ImmunotherapyRama Soundararajan, Jared J Fradette, Jessica M Konen, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 2009
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapySamanthi A Perera, Danan Li, Takeshi Shimamura, et al.
Pageof 68